Actinogen Medical Limited (ACW.AX)
AUD 0.03
(3.85%)
AUD 0.03
(3.85%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 9.93 Million AUD | 121.57% |
| 2023 | 4.48 Million AUD | 38.37% |
| 2022 | 3.23 Million AUD | 102.8% |
| 2021 | 1.59 Million AUD | -48.53% |
| 2020 | 3.1 Million AUD | -31.18% |
| 2019 | 4.5 Million AUD | 53.13% |
| 2018 | 2.94 Million AUD | 179.15% |
| 2017 | 1.05 Million AUD | -70.6% |
| 2016 | 3.58 Million AUD | 2238.29% |
| 2015 | 153.42 Thousand AUD | -15.33% |
| 2014 | 181.2 Thousand AUD | 5741.52% |
| 2013 | 3102.00 AUD | -93.98% |
| 2012 | 51.56 Thousand AUD | -45.41% |
| 2011 | 94.45 Thousand AUD | 1.78% |
| 2010 | 92.8 Thousand AUD | -27.57% |
| 2009 | 128.12 Thousand AUD | -17.8% |
| 2008 | 155.87 Thousand AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 FY | -416.83 Thousand AUD | -109.3% |
| 2024 Q2 | 697.06 Thousand AUD | 0.0% |
| 2024 Q4 | 8.81 Million AUD | 0.0% |
| 2023 Q2 | 803.04 Thousand AUD | 0.0% |
| 2023 FY | 4.48 Million AUD | 38.37% |
| 2023 Q4 | 3.67 Million AUD | 0.0% |
| 2022 Q2 | -200.2 Thousand AUD | 0.0% |
| 2022 FY | 3.23 Million AUD | 102.8% |
| 2022 Q4 | 3.43 Million AUD | 0.0% |
| 2021 Q4 | 1.77 Million AUD | 0.0% |
| 2021 Q2 | -177.98 Thousand AUD | 0.0% |
| 2021 FY | 1.59 Million AUD | -48.53% |
| 2020 Q4 | 2.57 Million AUD | 0.0% |
| 2020 FY | 3.1 Million AUD | -31.18% |
| 2020 Q2 | 532.87 Thousand AUD | 0.0% |
| 2019 Q4 | 4.6 Million AUD | 0.0% |
| 2019 FY | 4.5 Million AUD | 53.13% |
| 2019 Q2 | 79.82 Thousand AUD | 0.0% |
| 2018 Q2 | 219.11 Thousand AUD | 0.0% |
| 2018 FY | 2.94 Million AUD | 179.15% |
| 2018 Q4 | 3.08 Million AUD | 0.0% |
| 2017 Q2 | 79.98 Thousand AUD | 0.0% |
| 2017 FY | 1.05 Million AUD | -70.6% |
| 2017 Q4 | 1.33 Million AUD | 0.0% |
| 2016 Q2 | 1.41 Million AUD | 0.0% |
| 2016 Q4 | 2.54 Million AUD | 0.0% |
| 2016 FY | 3.58 Million AUD | 2238.29% |
| 2015 Q4 | 31.83 Thousand AUD | 0.0% |
| 2015 FY | 153.42 Thousand AUD | -15.33% |
| 2015 Q2 | 121.59 Thousand AUD | 0.0% |
| 2014 FY | 181.2 Thousand AUD | 5741.52% |
| 2014 Q4 | 14.14 Thousand AUD | 0.0% |
| 2014 Q2 | 167.06 Thousand AUD | 0.0% |
| 2013 FY | 3102.00 AUD | -93.98% |
| 2013 Q4 | 5740.00 AUD | 640.17% |
| 2013 Q3 | 775.50 AUD | -99.73% |
| 2013 Q2 | 290.27 Thousand AUD | 2151.92% |
| 2013 Q1 | 12.89 Thousand AUD | 0.0% |
| 2012 Q4 | 12.89 Thousand AUD | 0.0% |
| 2012 Q1 | 14.7 Thousand AUD | 0.0% |
| 2012 Q2 | 12.89 Thousand AUD | -12.34% |
| 2012 FY | 51.56 Thousand AUD | -45.41% |
| 2012 Q3 | 12.89 Thousand AUD | 0.0% |
| 2011 Q3 | 14.7 Thousand AUD | 0.0% |
| 2011 FY | 94.45 Thousand AUD | 1.78% |
| 2011 Q4 | 14.7 Thousand AUD | 0.0% |
| 2011 Q2 | 14.7 Thousand AUD | 21.51% |
| 2011 Q1 | 12.1 Thousand AUD | 0.0% |
| 2010 Q1 | 6397.25 AUD | 0.0% |
| 2010 FY | 92.8 Thousand AUD | -27.57% |
| 2010 Q4 | 12.1 Thousand AUD | 0.0% |
| 2010 Q3 | 12.1 Thousand AUD | 0.0% |
| 2010 Q2 | 12.1 Thousand AUD | 89.18% |
| 2009 FY | 128.12 Thousand AUD | -17.8% |
| 2009 Q1 | 3409.75 AUD | 0.0% |
| 2009 Q2 | 6397.25 AUD | 87.62% |
| 2009 Q3 | 6397.25 AUD | 0.0% |
| 2009 Q4 | 6397.25 AUD | 0.0% |
| 2008 FY | 155.87 Thousand AUD | 0.0% |
| 2008 Q4 | 3409.75 AUD | 0.0% |
| 2008 Q3 | 3409.75 AUD | 0.0% |
| 2008 Q2 | 3409.75 AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AdAlta Limited | 1.5 Million AUD | -558.625% |
| Acrux Limited | -1.28 Million AUD | 873.482% |
| AnteoTech Limited | 460.39 Thousand AUD | -2057.161% |
| Argenica Therapeutics Limited | 2.59 Million AUD | -282.284% |
| Arovella Therapeutics Limited | -25.97 Thousand AUD | 38328.97% |
| Anatara Lifesciences Ltd | -748.91 Thousand AUD | 1426.128% |
| Alterity Therapeutics Limited | 3.8 Million AUD | -161.013% |
| Amplia Therapeutics Limited | 4.01 Million AUD | -147.622% |
| Avecho Biotechnology Limited | -43.79 Thousand AUD | 22777.255% |
| Bio-Gene Technology Limited | -301.44 Thousand AUD | 3394.588% |
| Biome Australia Limited | 7.66 Million AUD | -29.491% |
| Biotron Limited | -40.49 Thousand AUD | 24623.443% |
| Botanix Pharmaceuticals Limited | -6.55 Million AUD | 251.59% |
| BTC Health Limited | 16.36 Thousand AUD | -60606.015% |
| Chimeric Therapeutics Limited | 7.45 Million AUD | -33.242% |
| CSL Limited | 15.28 Billion AUD | 99.935% |
| Clarity Pharmaceuticals Ltd | 11.5 Million AUD | 13.689% |
| Clinuvel Pharmaceuticals Limited | 78.09 Million AUD | 87.283% |
| Cynata Therapeutics Limited | 2.31 Million AUD | -328.888% |
| Dimerix Limited | 583.47 Thousand AUD | -1602.121% |
| EZZ Life Science Holdings Limited | 50.94 Million AUD | 80.506% |
| Hexima Limited | - AUD | -Infinity% |
| Island Pharmaceuticals Limited | 1.25 Million AUD | -693.52% |
| Immuron Limited | 3.33 Million AUD | -197.636% |
| Immutep Limited | 1.44 Million AUD | -587.823% |
| Imugene Limited | -5.83 Million AUD | 270.064% |
| Invex Therapeutics Ltd | 1.21 Million AUD | -719.258% |
| Memphasys Limited | 1606.00 AUD | -618300.0% |
| Nanollose Limited | -348.95 Thousand AUD | 2946.095% |
| Neuren Pharmaceuticals Limited | 205.17 Million AUD | 95.159% |
| Noxopharm Limited | -534.81 Thousand AUD | 1957.012% |
| NeuroScientific Biopharmaceuticals Limited | -91.33 Thousand AUD | 10973.473% |
| Nyrada Inc. | -5164.07 AUD | 192419.314% |
| Orthocell Limited | 3.68 Million AUD | -169.262% |
| PharmAust Limited | -1641.00 AUD | 605310.481% |
| Patrys Limited | 1.39 Million AUD | -612.363% |
| Paradigm Biopharmaceuticals Limited | 56.81 Thousand AUD | -17381.349% |
| Proteomics International Laboratories Limited | -1.12 Million AUD | 984.224% |
| Prescient Therapeutics Limited | 3.71 Million AUD | -167.525% |
| PYC Therapeutics Limited | 22.05 Million AUD | 54.978% |
| Race Oncology Limited | 1.38 Million AUD | -614.54% |
| Radiopharm Theranostics Limited | -21.3 Million AUD | 146.609% |
| Recce Pharmaceuticals Ltd | -366.76 Thousand AUD | 2807.844% |
| Starpharma Holdings Limited | 7.65 Million AUD | -29.705% |
| Telix Pharmaceuticals Limited | 308.5 Million AUD | 96.781% |
| Tissue Repair Ltd | 150.51 Thousand AUD | -6498.524% |
| Zelira Therapeutics Limited | 10.28 Thousand AUD | -96472.384% |